Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.

Abstract

The efficacy of FK463, a novel water-soluble lipopeptide, was evaluated in mouse models of pulmonary aspergillosis and was compared with that of amphotericin B (AMPH-B). In the pulmonary aspergillosis models induced by intranasal inoculation, FK463 exhibited good efficacy, with 50% effective doses in the range of 0. 26 to 0.51 mg/kg of body weight; these values were comparable to those of AMPH-B. In an Aspergillus target organ assay with immunosuppressed mice, under conditions of constant plasma levels of FK463, using a subcutaneously implanted osmotic pressure pump, a significant reduction in viable fungal cells was observed at plasma FK463 levels of 0.55 to 0.80 microgram/ml or higher. We conclude that FK463 is highly effective in the treatment of pulmonary aspergillosis in this animal model. These results indicate that FK463 may be a potent parenterally administered antifungal agent for pulmonary aspergillosis.

• Authors: S Matsumoto, Y Wakai, T Nakai, K Hatano, T Ushitani, F Ikeda, S Tawara, T Goto, F Matsumoto, S Kuwahara
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 44 Issue 3 Pg. 619-21 (Mar 2000) ISSN: 0066-4804 [Print] United States
• PMID: 10681328 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antifungal Agents
• Echinocandins
• Lipopeptides
• Lipoproteins
• Peptides, Cyclic
• Amphotericin B
• Micafungin

Topics

• Amphotericin B (therapeutic use)
• Animals
• Antifungal Agents (therapeutic use)
• Aspergillosis (drug therapy, microbiology)
• Aspergillus fumigatus (drug effects)
• Echinocandins
• Lipopeptides
• Lipoproteins (therapeutic use)
• Lung Diseases, Fungal (drug therapy, microbiology)
• Micafungin
• Mice
• Mice, Inbred ICR
• Microbial Sensitivity Tests
• Peptides, Cyclic (therapeutic use)
• Treatment Outcome